Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human safety, tolerability, and pharmacokinetics study of GLPG2451 alone and with GLPG2222 in healthy women
NL-OMON42997Phase 1Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of GLPG2451 and galicaftor in cystic fibrosis (CF), sponsored by Galapagos NV. Started Jun 2016; status: active, not recruiting.
02
Drugs
GLPG2451galicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON42997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42997.